Drug Profile
Zanubrutinib - BeiGene
Alternative Names: BGB-3111; BRUKINSALatest Information Update: 17 Apr 2024
Price :
$50
*
At a glance
- Originator BeiGene
- Developer BeiGene; Medison Pharma
- Class Amides; Antineoplastics; Phenyl ethers; Piperidines; Pyrazoles; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Phase III B-cell lymphoma
- Phase II/III Membranous glomerulonephritis
- Phase II CNS cancer; Diffuse large B cell lymphoma; Lupus nephritis; Lymphoma; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 Mar 2024 BeiGene completes a phase I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (PO) (NCT04436107)
- 07 Mar 2024 Launched for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO)
- 07 Mar 2024 Registered for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA (PO)